Event |
Unprecedented PK-PD correlations in-Vivo Pharmacology Learn how Christian Schnell, Associate Director Oncology NIBR, Novartis Pharma AG, Basel, CH reached his conclusions. Now available on demand. Expert Answers, Q&A Report Slide Deck, and On-demand Webinar< here >. | June 21, 2021
|
Event |
Have you ever wanted to get more out of your in-vivo pharmaceutical studies? Have a burning question about programmable pumps and implication of refinement and reduction of animal use? Join Christian Schnell in his upcoming webinar on Programmable pumps for compounds delivery in oncology research: implication for refinement and reduction of animal use. More information and registration < here > | May 17, 2021 |
News |
iPRECIO Programmable Minipumps for continuous delivery lenalidomide (LLD) in chronic lymphocytic leukemia (CLL). Video, https://youtu.be/d8CHR7et5zs from Start to 7 minutes: Rodent Studies of PK, Safety and Tolerability of LLD in Healthy and SCID Mice by Dr Jamie Oliver Chief Medical Officer of Starton Therapeutics (https://startontx.com/). IMS/SMP-300 for mice or larger used. Photo of SMP-200 for rats of larger shown. | February 24, 2021
|
News |
New review article on iPRECIO® – Linkedin Article – “Programmable pumps offer precise and translatable delivery of compounds to stress-free animals” https://www.linkedin.com/pulse/programmable-pumps-offer-precise-translatable-delivery-tsung-tan/?trackingId=i9CxNGMbQJye6JF6HVLJSw%3D%3D |
February 9, 2021 |
News |
US20200330445A1: Continuous delivery of lenalidomide and other immunomodulatory agents “After the tumor reached an average size of 100-150 mm, iPrecio pump was surgically implanted into each of the mice . Dosing began twenty – four hours post pump implantation. Each of Groups 3-6 was treated lenalidomide via continuous subcutaneous infusion at different hourly rate. The dosing lasted 14 days followed by one day off the treatment and lasted for another 14 days . The iPrecio pump was replaced after 14 days.” For full reference: – Click – |
December 1, 2020 |